SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE‐ARM, PHASE 2 TRIAL (ORIENT‐4). (12th June 2019)